Background {#Sec1}
==========

Age-related macular degeneration (AMD), also known as senile macular degeneration, is one of the primary causes of irreversible visual impairment among the elderly in the developed world \[[@CR1], [@CR2]\]. The incidence of AMD among Asian adults over the age of 50 is high \[[@CR3], [@CR4]\]. AMD has increasingly become a global issue. Several population-based studies have examined AMD worldwide \[[@CR5]--[@CR9]\]. Although the data are different in each study due to racial differences and participant recruitment, the obvious tendency towards an increased prevalence cannot be ignored.

AMD is a multifactorial disease due to interactions between genetic and environmental risk factors \[[@CR10]\]. Genome-wide association studies revealed that variations in or near the complement factor H (*CFH*), complement factor I (*CFI*), complement factor B (*CFB*), and complement 3 (*C3*) genes are significantly associated with AMD. In addition to mutations in complement genes, a polymorphism (rs10490924) in *ARMS2* (age-related maculopathy susceptibility 2), which encodes a protein that binds to the cell surface and enhances complement activation, shows the strongest association with AMD \[[@CR11]\]. Several challenges remain regarding *ARMS2*. First, the cellular expression and function of *ARMS2* in AMD are not fully understood. Second, whether the efficacy of medical treatment has a relationship with risk alleles remains controversial. Third, the *ARMS2* gene is present only in primates, which makes it difficult to construct animal models.

Given this situation and the rapid development of regenerative medical therapy, many researchers have performed deep and fruitful analyses of AMD and *ARMS2*. A recent report using a bisretinoid N-retinylidine-N-ethanolamine (A2E)-stressed human induced pluripotent stem cell (iPSC) model of AMD indicates that *ARMS2*/*HTRA1* compromises the superoxide dismutase 2 response, suggesting increased vulnerability to oxidative stress \[[@CR12]\]. In 2016, Saini et al. used a human iPSC model of AMD to demonstrate that nicotinamide altered disease-related phenotypes (*ARMS2*/*HTRA1*) by inhibiting drusen proteins and inflammatory and complement factors \[[@CR13]\]. With the help of stem cells or iPSC genetic models, researchers can better simulate the morbid state and then explore how the*ARMS2*/*HTRA1* genes affect AMD.

*ARMS2* variants and AMD {#Sec2}
========================

Because *ARMS2* is an evolutionarily recent primate-specific gene and because the *ARMS2*/*HTRA1* genes are found at a locus on chromosome 10q26 in a region with strong linkage disequilibrium \[[@CR14]\], whether *ARMS2* is the key gene leading to AMD is debatable.

Before we analyze the relationships between *ARMS2* polymorphisms and AMD, we must summarize the basic information available about *ARMS2* polymorphisms (Table [1](#Tab1){ref-type="table"}). Recently, Grassmann et al. \[[@CR15]\] demonstrated that genetic variants in or close to *ARMS2* but not *HTRA1* are responsible for disease susceptibility at the 10q26 locus. These results encourage a focus on functional analyses of *ARMS2* and its role in AMD pathogenesis \[[@CR15]\], even though a study by Yang et al. \[[@CR16]\] suggested that a variant of the *HTRA1* gene increased susceptibility to AMD. Jabbarpoor Bonyadi et al. considered that *ARMS2*/LOC387715 and *CFH* share a common pathway, possibly the complement system pathway, in AMD pathogenesis, and proposed that these genes might have a synergistic effect in AMD \[[@CR17]\]. Furthermore, *R38X*, *A69S*, and *R3H* (rs10490923), which are the three common coding variants in the *ARMS2* gene, were tested in a large case-control data set; the analysis showed that the *A69S* variant was significantly associated with AMD risk. The effect of the *R3H* variant was the opposite after adjustment for sex and age. Wang et al. \[[@CR18]\] showed that if the effect of *A69S* is removed, the inverse effect of *R3H* is no longer statistically significant, revealing the strong linkage disequilibrium in this region and showing that the *A69S* variant is a strong risk factor for AMD. Kortvely et al. \[[@CR19]\] found chimeric transcripts of the *PLEKHA1* (pleckstrin homology domain-containing protein family A member 1) gene that ended in *ARMS2*, which may explain how variants in this locus affect AMD. From these studies, it may be concluded that a close relationship between *ARMS2* variations and AMD exists, but the specific mechanism remains to be confirmed.Table 1Basic information for single nucleotide polymorphisms of four susceptibility loci in *ARMS2*SNPPhysical locationFunctionAlleleMinor alleleMinor allele frequencyrs1049092310:122454735Intron variant, missenseA/GA0.022rs1049092410:122454932Intron variant, missenseG/TT0.402rs273691110:122454839Intron variant, stop gainedC/TT0.122rs273691210:122456078Intron variantC/TT0.081

Medical treatment effects and AMD genetic variations {#Sec3}
====================================================

In recent years, the prevalence of AMD has increased, and medical treatment options are developing quickly \[[@CR20]\]. The argument that it is necessary to perform genotyping during the medical treatment of AMD has garnered attention over the past few years. Awh et al. \[[@CR21], [@CR22]\] suggested that the treatment response to antioxidants and zinc differs based on various combinations of *CFH* risk alleles and *ARMS2* risk alleles, an idea that was inconsistent with a previous study by Lee and Brantley \[[@CR23]\]. Chew et al. \[[@CR24]\] opposed this idea as well, demonstrating that the genotypes at the *CFH* and *ARMS2* loci did not significantly alter the benefits of Age-Related Eye Disease Study (AREDS) supplements, including a placebo, antioxidants, zinc, or antioxidants plus zinc. Smailhodzic et al. \[[@CR25]\] revealed that, although there was no significant association between changes in complement catabolism and *CFH* and *ARMS2* genotypes, there was evidence that the daily administration of 50 mg of zinc sulfate could inhibit complement catabolism in AMD patients with increased complement activation and slow AMD progression.

These findings raise concerns about genotyping during the medical treatment of AMD. To date, the results for AREDS supplement use have shown dissimilar effects with different genotypes (summarized in Table [2](#Tab2){ref-type="table"}). Basic research is greatly needed to resolve the question of whether genotyping is important.Table 2Effects of AREDS supplements on various combinations of *CFH* and *ARMS2* genotypesAuthorPatient informationGenotypeAREDS supplementOutcome measureResultAuthors' view with respect to genotyping utilityAwh et al. 2015 \[[@CR21]\]989 white patients with category 3 or 4 AMD0 or 1 *CFH* risk alleles and no *ARMS2* risk allelesComponents of the AREDS formulationSeven-year treatment-specific progression ratesPlacebo,22.6%;with antioxidants,9.17% (*P* = 0.033)Support0 or 1 *CFH* risk alleles and 1 or 2 *ARMS2* risk allelesPlacebo, 43.3%; zinc, 25.2% (*P* = 0.020); AREDS formulation (AF), 27.3% (*P* = 0.011)2 *CFH* risk alleles and no *ARMS2* risk allelesPlacebo, 17.0%; zinc, 43.2% (*P* = 0.023); AF, 40.2% (*P* = 0.039)2 *CFH* risk alleles and 1 or 2 *ARMS2* risk allelesNo treatment was better than placebo (48.4%)Lee et al. 2008 \[[@CR23]\]876 participants at high risk for developing advanced AMD*CFH*TTAntioxidants + zinc,\
Antioxidants,\
ZincProgression from high risk to advanced AMDThere was a nominally statistically significant interaction between AREDS supplements and the *CFH* Y402H genotype, and no significant treatment interactions were observed with *ARMS2*RejectTCCC*ARMS2*GGTGTTChew et al. 2014 \[[@CR24]\]1237 genotyped AREDS participants of Caucasian ethnicity who were at risk of developing late AMD*CFH*/*ARMS2* = xy, where x = *CFH* risk group, and y = *ARMS2* risk allelesPlacebo, antioxidants (vitamins C, E, beta-carotene), zinc with copper, or a combination of antioxidants, zinc, and copperProgression to late AMDNo clinically significant association between *CFH* and *ARMS2* genotypes and response to nutritional supplementsReject*000102101112202122*Smailhodzic et al. 2014 \[[@CR25]\]72 patients with various stages of AMD*CFH*TTA daily supplement of 50 mg zinc sulfate and 1 mg cupric sulfate for 3 monthsThe effect of zinc on complement activation in vitroThere was no significant association between changes in complement catabolism and *CFH* and *ARMS2* genotypes, but AMD progression was slowedRejectTCCC*ARMS2*GGTGTT

At present, vascular endothelial growth factor inhibitors (anti-VEGF) have become the first-line medication for the treatment of choroidal neovascularisation \[[@CR26]\]. Ranibizumab is used frequently for neovascular AMD and for polypoidal choroidal vasculopathy. Hu et al. \[[@CR27]\] indicated that, in patients with the *A69S* variant, the East Asian population showed better response to anti-angiogenic treatment than the Caucasian population on the basis of a meta-analysis. Piermarocchi et al. \[[@CR28]\] and Park et al. \[[@CR29]\] indicated that the TT genotype of *VEGFA* was associated with a significantly higher chance of visual gain than other genotypes. With respect to the tomographic outcome, the GG genotypes of both *ARMS2* and *HTRA1* were associated with larger central subfield macular thickness reduction than other genotypes, and no polymorphism showed a significant association with the frequency of injections. In contrast, complement factor H risk alleles affected the mid-term response to ranibizumab in exudative AMD, with worse 12-month best-corrected visual acuity (BCVA) outcomes, but there was no statistically significant association between *ARMS2* and the curative effect. Dedania et al. \[[@CR30]\] reviewed 16 different types of studies with follow-up periods that assessed 18 different genes and found that the frequency of injections may be associated with certain genotypes and that different genotypes might affect an individual's response to treatment for neovascular AMD.

Stem cell technology and *ARMS2* research {#Sec4}
=========================================

Stem cell transplantation as a potential treatment {#Sec5}
--------------------------------------------------

Many different forms of blindness result from the dysfunction or loss of the outer retina, including AMD and hereditary retinal degeneration. Various genetic diseases, such as Best disease, retinitis pigmentosa (RP), and Stargardt disease (STGD), are increasingly becoming important causes of irreversible blindness. However, effective treatments for these diseases have not yet been developed. Therefore, cell replacement is becoming a new method of treatment for outer-retina diseases. Fortunately, the differentiation of retinal pigment epithelium (RPE) from human embryonic stem cells (hESCs), from mesenchymal stem cells (MSCs), and from iPSCs has created many potential ways to replace dead or dying RPE. These cells have been shown to merge into the retina and regain functionality \[[@CR31]\].

hESC-RPE replacement therapy is one current research focus. Qu et al. \[[@CR32]\] successfully differentiated rat ESCs into glia-enriched retinal progenitor cells (RPCs) and retinal neuron-enriched RPCs in vitro; these cells might be useful for the treatment of such degenerative retinal diseases as AMD, RP, and STGD. Schwartz et al. \[[@CR33]\] investigated the primary safety and tolerability endpoints of the subretinal transplantation of hESC-derived RPE in nine patients with Stargardt's macular dystrophy (aged \>18 years) and nine with atrophic AMD (aged \>55 years). This study provided the first evidence of the medium- to long-term safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with Stargardt's macular dystrophy and AMD \[[@CR33]\]. Buchholz et al. \[[@CR34]\] described a new protocol that was useful for rapidly generating RPE for transplantation. Although RPE from hESCs is an ideal RPE source for patients with dry AMD, it has potential risks. Ethical issues and lifelong immune rejection limit its application for modeling and transplant therapy in the clinical setting.

Recently, two encouraging reports using a rat model showed that erythropoietin (EPO) gene modification in MSCs may represent an even better source of RPE \[[@CR35], [@CR36]\]. As the derivation of RPE from MSCs is a new method for transplantation, further research in animal models is required to verify these results.

iPSCs, which originate from somatic cells, bear patient-specific genetic or protein information that may have potential for use in the development of personalized therapeutic approaches. Silva et al. \[[@CR37]\] proposed standardized practices for iPSC generation and analyzed bottlenecks and future directions of this technique. Gong et al. \[[@CR38]\] found that protein-induced pluripotent stem cells can be differentiated into RPE-like cells using a method that shows an increased safety profile, a critical consideration for the development of better treatments for degenerative retinal diseases such as AMD. Mandai et al. \[[@CR39]\] demonstrated the feasibility of transplanting a sheet of RPE cells differentiated from iPSCs into a patient with neovascular AMD one year after surgery. The transplanted cell sheet remained intact; however, the BCVA neither improved nor worsened, and Central Macular Edema (CME) was present \[[@CR39]\]. Although iPSCs have enormous potential for clinical applications, they also present several challenges. For example, they are derived from the patients themselves and thus may carry disease-causing genes, and they pose a potential risk of carcinoma \[[@CR40], [@CR41]\]. In future iPSC research, investigators should conduct detailed studies that focus on high-yield components to better apply iPSCs to humans.

*ARMS2* research based on the iPSC-RPE AMD model {#Sec6}
------------------------------------------------

The development of iPSC technology has caused a stunning shift in the field of stem cell biology and has provided an alternative source of pluripotent cells \[[@CR42]\]. The pioneering accomplishment in 2006 by the Yamanaka group had important implications for the field \[[@CR43]\]. Several retinal models have been developed. Singh et al. \[[@CR44]\] used Best patient-specific iPSC-derived RPE to simulate some of the cellular disease endophenotypes in RPE cells; Megaw et al. \[[@CR45]\] used human iPSCs with RP-causing mutations to examine the pathophysiology of disease; and Yvon et al. \[[@CR46]\] published a comprehensive paper about using stem cells to model diseases of the outer retina.

Genome-wide association studies have identified risk alleles for the disease, such as those of the *ARMS2* and *HTRA1* genes, but how these alleles lead to pathology remains unclear. There is currently a dearth of appropriate models for AMD; autopsied eyes from end-stage patients already possess terminal changes and therefore cannot be used to determine how abnormal gene expression can lead to RPE pathology, and mice do not have maculae \[[@CR47]\]. As noted above, iPSC-RPE derived from AMD patients can model aspects of AMD in culture and is a better model than RPE stem cells. There is ample opportunity to study the *ARMS2* gene using iPSC-RPE cells that are derived from AMD patients themselves and express multiple biomarkers associated with AMD and AMD-associated proteins.

Superoxide dismutase 2 (SOD2), encoded by the *SOD2* gene, is a mitochondrial enzyme that protects cells from oxidative damage \[[@CR48]\]. Yang et al. \[[@CR12]\] created a model of AMD by obtaining patient-specific iPSC-derived RPE and pharmacologically accelerating the ageing process by treatment with A2E and blue light. They found with this iPSC-RPE AMD model that the *ARMS2*/*HTRA1* risk alleles decreased SOD2 defense, making RPE more susceptible to oxidative damage and thereby contributing to AMD pathogenesis \[[@CR12]\]. However, these findings would be better supported if they were reproduced using additional patient samples with identical *ARMS2*/*HTRA1* risk alleles. Using this ground-breaking iPSC model, researchers can better assess the effects of *ARMS2*/*HTRA1* risk alleles on AMD pathogenesis and identify pathways that can be therapeutically targeted. Furthermore, Saini et al. \[[@CR13]\] revealed the function of nicotinamide in AMD using the iPSC model; they noted that ICAM1, which has been linked to the development of the wet form of AMD, was strongly upregulated in human AMD *ARMS2*/*HTRA1* iPSC-RPE and was markedly inhibited by nicotinamide \[[@CR13]\].

Due to the 100% linkage disequilibrium between the*ARMS2* and *HTRA1* risk alleles, it has not been possible to establish which of these genes is the causal variant for AMD. Fortunately, in 2013, two American laboratories discovered that the clustered regularly interspaced short palindromic repeats/Cas-9(CRISPR/Cas9) system of prokaryotic adaptive immunity might be used as a new method for genome editing \[[@CR49]\]. This technique may provide insight into iPSC-RPE AMD modeling. Researchers can now edit the genotypes at will, and the resulting iPSC-RPE cells can serve as models of specific *ARMS2* risk alleles. This strategy is similar in principle to deriving iPSCs from patients with identical *ARMS2*/*HTRA1* risk alleles. Furthermore, the genome-editing model has overtaken models using patient-specific hESCs due to the ethical, technical, and political concerns associated with such cells \[[@CR50]\].

Conclusions {#Sec7}
===========

For the purposes discussed above, further study is needed for a greater understanding of the characteristics of *ARMS2* gene-related AMD modeled using stem cell technology. The identification of additional disease-specific biological characteristics and a fuller understanding of the mechanisms of induction and migration will make drug discovery and cell therapy gradually change from dream to reality. Although they remain difficult to apply to clinical practice, several researchers have found that iPSCs have great potential for regenerative medicine. Continuing the progress of cell transplantation and regeneration in the retina and in AMD genetic models will prove to be beneficial. Regenerative medicine in the eye must be further improved so that it can be more effectively employed.

Although several issues remain to be solved, the findings discussed above provide new ideas for continuing exploration of the mechanisms by which *ARMS2* high-risk alleles lead to AMD; such research will provide important guidance for the treatment of AMD.
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